Clearstead Advisors LLC Boosts Stock Holdings in Eli Lilly and Company $LLY

by · The Cerbat Gem

Clearstead Advisors LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 49,407 shares of the company’s stock after purchasing an additional 679 shares during the quarter. Clearstead Advisors LLC’s holdings in Eli Lilly and Company were worth $53,097,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company during the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares during the last quarter. 10Elms LLP boosted its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. boosted its holdings in Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the last quarter. Finally, Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $33,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

  • Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
  • Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
  • Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
  • Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Analyst Ratings Changes

LLY has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Berenberg Bank lifted their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Argus lifted their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Bank of America lowered their target price on Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,220.37.

View Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Trading Up 0.1%

Shares of Eli Lilly and Company stock opened at $1,066.59 on Monday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The stock’s 50-day simple moving average is $942.87 and its 200 day simple moving average is $1,004.53. The stock has a market capitalization of $1.00 trillion, a P/E ratio of 37.89, a P/E/G ratio of 1.16 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the business posted $3.34 EPS. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).